CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

NeoGenomics Raises 2026 Revenue Guidance to $807 Million-$809 Million

By Public Technologies
  • NeoGenomics raised its 2026 revenue forecast on October 28 to $807 million-$809 million from $802 million-$806 million.
  • Adjusted EBITDA guidance increased to about $60 million from $56 million-$58 million, implying roughly 38% annual growth.
  • The outlook assumes low-teens clinical revenue growth, with next-generation sequencing revenue expected to rise more than 25%.
  • Adjusted gross margin is expected to expand by more than 150 basis points for the full year.
  • Third-quarter revenue rose 11% to $209 million; adjusted EBITDA increased 53% to $19 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk